Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
0.810
-0.010 (-1.21%)
At close: Apr 28, 2026, 4:00 PM EDT
0.800
-0.010 (-1.25%)
Pre-market: Apr 29, 2026, 8:12 AM EDT

Company Description

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.

The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.

It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases.

Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International, Inc.
Dyadic International logo
Country United States
Founded 1979
IPO Date Nov 5, 2004
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Mark Emalfarb

Contact Details

Address:
1044 North U.S. Highway One, Suite 201
Jupiter, Florida 33477-5094
United States
Phone 561 743 8333
Website dyadic.com

Stock Details

Ticker Symbol DYAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001213809
CUSIP Number 26745T101
ISIN Number US26745T1016
Employer ID 45-0486747
SIC Code 2836

Key Executives

Name Position
Mark A. Emalfarb Founder, Chief Executive Officer and Director
Joseph P. Hazelton President and Chief Operating Officer
Ping Wang Rawson CPA, M.B.A. Chief Financial Officer
Ana Gómez Rodriguez Secretary of the Board

Latest SEC Filings

Date Type Title
Mar 30, 2026 8-K Current Report
Mar 25, 2026 8-K Current Report
Mar 25, 2026 10-K Annual Report
Mar 6, 2026 8-K Current Report
Mar 6, 2026 424B5 Filing
Feb 17, 2026 SCHEDULE 13G/A Filing
Dec 29, 2025 8-K Current Report
Dec 29, 2025 8-K Current Report
Nov 14, 2025 SCHEDULE 13G/A Filing
Nov 12, 2025 8-K Current Report